FreeTender
Accepting bidsitbFinland

Finland – Laboratory reagents – MLPA-Based CNV Testing for BRCA1/BRCA2

Issued by HUS Group, the joint authority for Helsinki and Uusimaa · via TED — Tenders Electronic Daily (EU)

Verify & apply on the official portal →
Published
8 Oct 2026
Closes
9 Nov 2026, 23:59 UTC
Reference
694407-2026
Location
Finland
Sector
Healthcare & Pharma
Type
goods

At a glance

HUS Group, the joint authority for Helsinki and Uusimaa in Finland has published an invitation to bid in healthcare & pharma: “Finland – Laboratory reagents – MLPA-Based CNV Testing for BRCA1/BRCA2”. Submissions close on 9 November 2026, 33 days from today. Quote reference 694407-2026 in any correspondence with the buyer. One document is attached to this notice. There are 55 open healthcare & pharma notices in Finland on FreeTender. Bids are submitted to the buyer through TED — Tenders Electronic Daily (EU), not through FreeTender.

Details

HUSLAB Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic and follow-up genetic testing services for patients within the Helsinki University Hospital area. The object of the procurement is an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licences and other components required for routine use of the assay and generation of reportable patient results. The procurement also includes any software, licences, user rights, technical support and related services required for operation of the assay, data analysis and result reporting The contract period shall be two (2) years, after which the agreement shall continue for an indefinite period until terminated in accordance with the terms of the agreement. The estimated annual consumption is approximately 1600 reportable patient samples. The estimate is non-binding and provided for information purposes only. The contracting entity does not commit to any specific purchase volumes or quantities. Actual purchases will be made based on the contracting entity's needs and may be higher or lower than estimated.

Lots Lot 1 — MLPA-Based CNV Testing for BRCA1/BRCA2

Buyer: HUS Group, the joint authority for Helsinki and Uusimaa

Buyer country: FIN

Procedure: open

CPV code: 33696500

Full notice, tender documents and how to bid are on the official TED page (link above).

Context for bidders

There are 55 open Healthcare & Pharma tenders in Finland. This one closes in 33 days.

Documents

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
Common bidding mistakes to avoid →Writing a winning proposal

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →